New antidiabetic therapy and HFpEF: light at the end of tunnel?

New antidiabetic therapy that includes sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor (GLP-1R) agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors showed significant benefit on cardiovascular outcomes in patients with and without type 2 diabetes mellitus, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Tadic, Marijana, Sala, Carla, Saeed, Sahrai, Grassi, Guido, Mancia, Giuseppe, Rottbauer, Wolfang, Cuspidi, Cesare
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197886/
https://www.ncbi.nlm.nih.gov/pubmed/33843015
http://dx.doi.org/10.1007/s10741-021-10106-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197886/
https://www.ncbi.nlm.nih.gov/pubmed/33843015
http://dx.doi.org/10.1007/s10741-021-10106-9

Ejemplares similares